| Outcome Measures: |
Primary: Reduction in 24-hour ambulatory systolic blood pressure(SBP), The comparison of the reduction in 24-hour ambulatory systolic blood pressure from baseline between the two groups, From enrollment to the end of treatment at 12 weeks | Secondary: Reduction in 24-hour ambulatory diastolic blood pressure(DBP), The comparison of the reduction in 24-hour ambulatory diastolic blood pressure from baseline between the two groups, From enrollment to the end of treatment at 12 weeks|Changes in daytime and nighttime ambulatory blood pressure, The comparison of the changes in daytime and nighttime ambulatory blood pressure between the two groups. (The mean daytime blood pressure is defined as the average of hourly measurements taken between 6:00 and 22:00, and the mean nighttime is defined as the average of hourly measurements taken between 22:00 and 6:00.), From enrollment to the end of treatment at 12 weeks|Rate of dipper blood pressure restoration, The comparison of the proportion of subjects in each group who achieve a dipper blood pressure pattern, defined as a nighttime blood pressure reduction of 10-20% in both systolic and diastolic blood pressure., From enrollment to the end of treatment at 12 weeks|Rate of blood pressure achievement, The comparison of the proportion of subjects in each group who achieve blood pressure targets (SBP \< 130 mmHg and DBP \< 80 mmHg), From enrollment to the end of treatment at 12 weeks|Rate of hypertension treatment response, The comparison of the proportion of subjects in each group who achieve hypertension treatment response, defined as: SBP \< 140 mmHg and/or a reduction from baseline of ≥ 20 mmHg; DBP \< 90 mmHg and/or a reduction from baseline of ≥ 10 mmHg; both of them, From enrollment to the end of treatment at 12 weeks|Improvement in diabetes condition, Comparison of reductions in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) between the two groups, From enrollment to the end of treatment at 12 weeks|Improvement in Renal Function, The comparison of reductions in serum creatinine, urine albumin/creatinine ratio, and blood urea nitrogen between the two groups, From enrollment to the end of treatment at 12 weeks|Medication utilization, The comparison of dose escalation proportions and the proportion of subjects requiring adjunctive nifedipine controlled-release tablets between the two groups, From enrollment to the end of treatment at 12 weeks|Safety assessments, Safety assessments included monitoring of all adverse events (AEs), serious AEs (SAEs), and regular monitoring of vital signs and clinical laboratory tests., From enrollment to the end of treatment at 12 weeks
|
